How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Artificial intelligence (AI) is reshaping the pharmaceutical industry, driving advances from drug discovery and clinical trial acceleration to manufacturing optimisation and commercialisation. And ...

Artificial Intelligence (AI) has achieved remarkable successes in recent years. It can defeat human champions in games like Go, predict protein structures with high accuracy, and perform complex tasks ...

Christina Majaski writes and edits finance, credit cards, and travel content. She has 14+ years of experience with print and digital publications. Charlene Rhinehart is a CPA , CFE, chair of an ...

Julie Young is an experienced financial writer and editor. She specializes in financial analysis in capital planning and investment management. Gordon Scott has been an active investor and technical ...

Getting good at LeetCode Java isn’t just about solving problems; it’s about having a good plan. You need to know where to start, what tools to use, and how to keep going when things get tough. This ...